ALKS - Alkermes plc - Stock Price & Catalysts • BiopharmIQ

BiopharmIQ

Try Pro Free Already have an account? Login

Enterprise Value

4.952B

Cash

600.5M

Avg Qtr Burn

-5.484M

Short % of Float

5.12%

Insider Ownership

1.75%

Institutional Own.

-

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Aristada (aripiprazole lauroxil) Details Schizophrenia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vivitrol (naltrexone) Details Alcohol dependence and opioid dependence treatment	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LYBALVI (ALKS 3831) Details Bipolar disease, Mental health, Schizophrenia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nemvaleukin alfa (ALKS-4230) (IL-2) + KEYTRUDA (PD-1) Details Ovarian cancer, Solid tumor/s, Cancer, Platinum-resistant ovarian cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nemvaleukin Alfa (nemvaleukin) Details Cancer, Melanoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nemvaleukin Alfa (ALKS 4230) (IL-2) Details Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.